Lack of tolerable treatment options for patients with schizophrenia

Código QR

Lack of tolerable treatment options for patients with schizophrenia

Leslie Citrome,1 Anna Eramo,2 Clement Francois,2 Ruth Duffy,3 Susan N Legacy,3 Steve J Offord,3 Holly B Krasa,3 Stephen S Johnston,4 Alice Guiraud-Diawara,5 Siddhesh A Kamat,3 Patricia Rohman3 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, 2Lundbeck, Deer...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, Rohman P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	schizophrenia atypical antipsychotics tolerability comorbidities treatment Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f52fce680c02433a94e07a79f62deb18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Octavian Vasiliu
Publicado: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy Á, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
por: Barabássy Á, et al.
Publicado: (2021)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
por: Patrick Köck, et al.
Publicado: (2021)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Ward K, et al.
Publicado: (2019)

Esquizofrenia y su asociación con enfermedades médicas crónicas
por: Orellana,Gricel, et al.
Publicado: (2017)

A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
por: Li Y, et al.
Publicado: (2021)

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review
por: Karson C, et al.
Publicado: (2016)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Tzu-Pei Yeh, et al.
Publicado: (2021)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
por: Yalin N, et al.
Publicado: (2020)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden J, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome L
Publicado: (2018)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
por: Lei Chen, et al.
Publicado: (2021)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
por: Shiraz Hussain, et al.
Publicado: (2021)

A systematic review of the effects of psychiatric medications on social cognition
por: Zoë Haime, et al.
Publicado: (2021)

Use of atypical antipsychotics in the elderly: a clinical review
por: Gareri P, et al.
Publicado: (2014)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir S, et al.
Publicado: (2016)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
por: Findling RL, et al.
Publicado: (2018)

Diagnosis and Treatment of Depression in Patients with Schizophrenia
por: Sergey N. Mosolov
Publicado: (2020)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic M, et al.
Publicado: (2018)

A Multimodal Fusion Analysis of Pretreatment Anatomical and Functional Cortical Abnormalities in Responsive and Non-responsive Schizophrenia
por: Chenyang Yao, et al.
Publicado: (2021)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
por: Bracha Erlanger Avigdor, et al.
Publicado: (2021)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga S, et al.
Publicado: (2021)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Schizophrenia research and treatment

Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review
por: Sajatovic M, et al.
Publicado: (2017)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes JM, et al.
Publicado: (2021)

Irreversible Primary Visual Cortex Impairment in a Mouse Model of High-Risk Schizophrenia
por: Chen X, et al.
Publicado: (2021)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
por: Huang YC, et al.
Publicado: (2018)